Asia Pacific

Europe, Middle East & Africa (EMEA)

Latin America

North America

  • Home
  • Congress & Events
  • EFFICACY AND SAFETY OF ATEZOLIZUMAB CONCURRENT WITH RADIOTHERAPY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER: An interim analysis of the ATEZOBLADDERPRESERVE phase II trial (SOGUG-2017-A-IEC(VEJ)-4)

EFFICACY AND SAFETY OF ATEZOLIZUMAB CONCURRENT WITH RADIOTHERAPY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER: An interim analysis of the ATEZOBLADDERPRESERVE phase II trial (SOGUG-2017-A-IEC(VEJ)-4)

ATEZO BLADDER PRESERVE is an open, multicenter Phase II trial in patients with a confirmed diagnosis of muscle-invasive bladder cancer (MIBC) in clinical stages cT2-T4a N0 M0 who are not candidates for radical cystectomy. This presentation reports on the interim safety and efficacy findings of atezolizumab concurrent with external beam radiotherapy for the treatment of MIBC with the intent to preserve the bladder.

Share this page

Close Tooltip
Copy Link Tooltip

Copy page URL

of 0
Download Current View

Related content

document
Congresses & Events

Congresses & Events

Dec 4, 2024

Disease-free survival and overall survival in patients with high-risk muscle-invasive bladder cancer who have persistent circulating tumor DNA-negative biomarker status post-cystectomy: IMvigor011 study surveillance analysis
Oncology Oncology
document
Congresses & Events

Congresses & Events

Oct 23, 2023

A global, multicentre, open-label, randomised phase II trial of tobemstomig (tobe) with or without tiragolumab (tira) vs atezolizumab (atezo) in patients (pts) with untreated metastatic urothelial cancer (mUC) ineligible for platinum-based chemotherapy (chemo)
Oncology Oncology
document
Congresses & Events

Congresses & Events

Oct 22, 2023

A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in non-urothelial, muscle invasive bladder cancer (ABACUS-2)
Oncology Oncology

Welcome to Medically

The Roche Science Hub

This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management.

I am a healthcare professional

Not a healthcare professional? Browse:

Roche's patients website Roche.com

This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. This global website is intended for healthcare professionals outside the UK, US, Canada, and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications, and services that are not approved or valid in your country. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

Leave Site Stay on Medically

You are Leaving the Global Medically Site

By following this link, you are being redirected to another Roche page.

Leave Site Stay on Medically